Sangamo Therapeutics Inc.

Sangamo Therapeutics Inc. is a biotechnology company focused on translating groundbreaking genomic therapies into transformative treatments for patients with genetic diseases. Specializing in proprietary zinc finger DNA-binding proteins (ZFPs), they aim to precisely edit and modulate gene expression. This innovative technology positions Sangamo as a leader in the realm of gene therapy, cell therapy, and genome editing. The company's efforts target significant medical areas including hemophilia, beta-thalassemia, Fabry disease, and several neurological conditions. With its robust pipeline, Sangamo collaborates with major pharmaceutical companies to harness the potential of its genome editing tools. Operating in the rapidly evolving biotech industry, Sangamo's work contributes significantly to advancements in precision medicine. Additionally, its achievements in engineering ZFPs for human therapeutics underscore its role in pushing the boundaries of genetic medicine, with a commitment to addressing complex genetic anomalies and untreated rare diseases across the globe.